BioSpace News Archive

Ikena Oncology, Inc. today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the presentation of data supporting the potential of its first and lead product candidate, BSB-1001, at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Medicenna Therapeutics Corp. today announced new safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first four dose escalation cohorts of the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist.

Sensei Biotherapeutics, Inc. today presented preclinical data for SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei’s discovery-stage SNS-102 program, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) therapies, including anti-PD-1.

Codiak BioSciences, Inc. today announced new preclinical data from its exoASO™-STAT6 and exoASO™-C/EBPβ programs.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced the presentation of data on TPST-1120, an oral selective peroxisome-proliferator activated receptor-alpha (PPAR-α) antagonist, and TPST-1495, a dual antagonist of both EP2 and EP4 prostaglandin (PGE2) receptors, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Allakos Inc. inflammatory and proliferative diseases, today announced a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

Immutep Limited today announces encouraging initial clinical data from the investigator-initiated INSIGHT-003 trial has been published in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.

Allogene Therapeutics, Inc. today presented pre-clinical data on a novel approach to immune “cloaking” designed to protect AlloCAR T™ cells from rapid host rejection.